Chase banks $21M round for Alzheimer's drug research

Promising to use its technology to enhance the efficacy and safety of currently approved Alzheimer's drugs, Chase Pharmaceuticals says it has now added $21 million in new venture cash. The Series B financing was led by New Rhein Healthcare Investors, with Edmond de Rothschild Investment Partners and Cipla Ventures adding funds. The original venture investor, Brain Trust Accelerator Fund, also participated. Thomas Chase, the former scientific director of the National Institute of Neurological Disorders and Stroke and Kathleen Clarence-Smith, former head of CNS development at Sanofi ($SNY), Roche ($RHHBY) and Otsuka, founded the company in 2007. Release